TAXIS Pharmaceuticals, Inc. Email Format
Pharmaceutical ManufacturingUnited States11-50 Employees
TAXIS Pharmaceuticals is a United States based biotechnology company focused on addressing antimicrobial resistance. It develops therapies designed to be used in combination with FDA-approved antibiotics to restore their effectiveness against resistant infections. The company aims to tackle the root causes of resistance and operates in the pharmaceutical manufacturing sector by pursuing anti-resistance therapies that complement existing treatments. Its pipeline includes at least one investigational therapy that has completed Phase 1 trials, with additional products in development, and the firm is a small, research-focused organization. In May 2026, TAXIS announced that its scientific team will present preclinical data from two antibiotic development programs at the American Society for Microbiology conference in Washington, DC, scheduled for June 4 to 7, 2026.